Johnson & Johnson $JNJ Shares Sold by MetLife Investment Management LLC

Key Points

• MetLife Investment Management LLC sold 11,915 shares of Johnson & Johnson, reducing its holdings by 1.9%, now owning 625,434 shares worth approximately $103.72 million.
• Several institutional investors have adjusted their stakes in Johnson & Johnson, with notable increases from Lantz Financial LLC and Tokio Marine Asset Management Co. Ltd., indicating ongoing institutional interest.
• Johnson & Johnson recently reported quarterly earnings of $2.77 EPS, surpassing estimates, alongside a cash dividend of $1.30 due to be paid on September 9th, reflecting a 2.9% yield.

MetLife Investment Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 625,434 shares of the company's stock after selling 11,915 shares during the quarter. Johnson & Johnson makes up about 0.6% of MetLife Investment Management LLC's portfolio, making the stock its 23rd biggest holding. MetLife Investment Management LLC's holdings in Johnson & Johnson were worth $103,722,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lantz Financial LLC boosted its stake in Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in Johnson & Johnson during the 4th quarter worth $453,000. Joel Isaacson & Co. LLC boosted its stake in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares during the last quarter. State of Wyoming boosted its stake in Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its stake in Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after purchasing an additional 4,816 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Stock Up 0.1%

Shares of JNJ opened at $179.0980 on Friday. The firm has a market cap of $431.33 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The company's 50-day moving average price is $163.48 and its 200 day moving average price is $159.26. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.